Sirtex achieves 10 years of quarterly sales growth
Sirtex Medical (ASX:SRX) has reported a 27.1% sequential increase in dose sales for its SIR-Spheres target radiation therapy for liver cancer in the June quarter.
Sales increased across all regions, from an 11.7% growth in APAC to a 33% increase in the Americas. The EMEA region recorded growth of 16.7%.
Sirtex CEO Gilman Wong noted that the quarterly growth marks a significant milestone. “Sirtex has now achieved the impressive record of 10 years of consistent quarterly growth and we expect this trend will continue.”
The company is currently focused on its 2020Vision strategy, which involves an attempt to accelerate sales growth in the medium to long term, he said.
“We will no longer report quarterly dose sales results; however, we will be reporting on key elements of our 2020Vision strategy.”
In March, Sirtex announced it had teamed up with France’s Guerbet to evaluate combining SIR-Spheres with Guerbet’s Lipidol Ultra Fluid in treatments for liver cancers.
Targets include hepatocellular carcinoma, metastatic colorectal cancer and metastatic neuroendocrine tumours. This marks the first time the two products are being formally evaluated together or sequentially.
Sirtex Medical (ASX:SRX) shares were trading 4.02% higher at $18.35 as of around 2 pm on Friday.
'Longevity gene' could reverse damage from rapid aging disease
A gene found in supercentenarians, who live exceptionally long lives, could counteract the...
How a common gene mutation increases liver disease risk
Liver damage can be caused in people after exposure to high levels of acrolein, especially in...
Gene therapy slows Huntington's disease progression in trial
Patients receiving the treatment were found to experience 75% less progression of the disease...
